Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, April 10, 2015, 41 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $138.68 to $5,000,009.87.

Highlighted Stocks Traded by Insiders:

Gevo (GEVO) - FREE Research Report

Willis Mike, who is Cfo at Gevo, sold 713 shares at $0.19 on April 10, 2015. Following this transaction, the Cfo owned 113,203 shares meaning that the stake was reduced by 0.63% with the 713-share transaction.

The shares most recently traded at $0.19, down $0.00, or 2.37% since the insider transaction. Historical insider transactions for Gevo go as follows:

  • 4-Week # shares bought: 181,484
  • 4-Week # shares sold: 8,318
  • 12-Week # shares bought: 181,484
  • 12-Week # shares sold: 35,688
  • 24-Week # shares bought: 181,484
  • 24-Week # shares sold: 98,610

The average volume for Gevo has been 4.6 million shares per day over the past 30 days. Gevo has a market cap of $27.6 million and is part of the basic materials sector and chemicals industry. Shares are down 37.81% year-to-date as of the close of trading on Friday.

Gevo, Inc., a renewable chemicals and biofuels company, focuses on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The company operates in two segments, Gevo, Inc.; and Gevo Development/Agri-Energy. Currently, there are 2 analysts who rate Gevo a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GEVO - FREE

TheStreet Quant Ratings rates Gevo as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Gevo Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

LDR (LDRH) - FREE Research Report

Lavigne Christophe, who is President & CEO at LDR, sold 20,000 shares at $38.19 on April 10, 2015. Following this transaction, the President & CEO owned 751,196 shares meaning that the stake was reduced by 2.59% with the 20,000-share transaction.

The shares most recently traded at $38.40, up $0.21, or 0.56% since the insider transaction. Historical insider transactions for LDR go as follows:

  • 4-Week # shares bought: 110,000
  • 4-Week # shares sold: 795
  • 12-Week # shares bought: 110,000
  • 12-Week # shares sold: 536,944
  • 24-Week # shares bought: 110,000
  • 24-Week # shares sold: 611,944

The average volume for LDR has been 224,600 shares per day over the past 30 days. LDR has a market cap of $1.0 billion and is part of the health care sector and health services industry. Shares are up 15.89% year-to-date as of the close of trading on Friday.

LDR Holding Corporation, a medical device company, focuses on designing and commercializing various surgical technologies for the treatment of patients suffering from spine disorders in the United States and internationally. Currently, there are 5 analysts who rate LDR a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LDRH - FREE

TheStreet Quant Ratings rates LDR as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow. Get the full LDR Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Usana Health (USNA) - FREE Research Report

Gull Global Ltd, who is 10% Owner at Usana Health, sold 7,000 shares at $113.54 on April 10, 2015. Following this transaction, the 10% Owner owned 6.5 million shares meaning that the stake was reduced by 0.11% with the 7,000-share transaction.

The shares most recently traded at $117.80, up $4.26, or 3.62% since the insider transaction. Historical insider transactions for Usana Health go as follows:

  • 4-Week # shares sold: 19,780
  • 12-Week # shares sold: 19,780
  • 24-Week # shares sold: 19,780

The average volume for Usana Health has been 76,500 shares per day over the past 30 days. Usana Health has a market cap of $1.5 billion and is part of the health care sector and drugs industry. Shares are up 15.33% year-to-date as of the close of trading on Friday.

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease worldwide. The company has a P/E ratio of 20.7. Currently, there are no analysts who rate Usana Health a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on USNA - FREE

TheStreet Quant Ratings rates Usana Health as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Usana Health Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null